## **Description of Additional Supplementary Information**

File Name: Supplementary Data 1.

Description: Oslo2 45 BC quantitative proteome data, related to figures 1-6.

File Name: Supplementary Data 2.

Description: Correlation matrix of FDA approved drug targets, related to figure 4.

File Name: Supplementary Data 3.

Description: EGFR and MET IF scores, related to figure 4.

File Name: Supplementary Data 4.

Description: mRNA-protein correlation, related to figure 5.

File Name: Supplementary Data 5.

Description: CNA-mRNA/protein association, related to figure 6.

File Name: Supplementary Data 6.

Description: Novel peptide and SAAV identifications, related to figure 7.

File Name: Supplementary Data 7.

Description: Synthetic peptide validation of novel peptides and SAAV, related to figure 7.

File Name: Supplementary Data 8.

Description: Novel peptide identifications in tumor and normal tissue, related to Supplementary

Figure 14.